Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,966 DKK | +0.46% | -2.12% | -8.79% |
Apr. 30 | Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer | MT |
Apr. 30 | Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.79% | 18.14B | |
-1.78% | 102B | |
+2.44% | 96.09B | |
+2.13% | 22.28B | |
-16.93% | 21.4B | |
-39.98% | 17.02B | |
-13.89% | 16.09B | |
+5.23% | 13.83B | |
+33.14% | 11.97B | |
+312.80% | 8.78B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- SVB Securities Adjusts Price Target on Genmab A/S to $36 From $33, Maintains Market Perform Rating